BDBM107695 US11426393, Compound Table XV.1::US8598210, Table XV, 1::US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyridine-2- carbonyl]-amino}-acetic acid methyl ester::US9598370, Example 00126::USRE47437, Example {[5-(3-chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester

SMILES COC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1

InChI Key InChIKey=LQWXMRRGVHUWEN-UHFFFAOYSA-N

Data  10 IC50  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 107695   

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.14E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  9.90E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.80E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.14E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.14E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  9.90E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.14E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  9.90E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.14E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  9.90E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 ceils per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent